Document:

EX-10.1

SETTLEMENT AGREEMENT AND NON-EXCLUSIVE PATENT CROSS-LICENSE

This Settlement Agreement and Non-Exclusive Patent Cross-License (“Agreement”) is made and
entered into effective this 29th day of January, 2010 (the “Effective Date”), by and between,
Boston Scientific Corporation, and Boston Scientific Scimed, Inc., formerly Scimed Life Systems,
Inc. (hereinafter collectively “Boston Scientific”), on one hand, and, Johnson & Johnson (“J&J”)
and Cordis Corporation (“Cordis”, and together with J&J, “J&J/Cordis”), on the other hand
(collectively, the “Parties,” or each separately, a “Party”).

RECITALS

A. WHEREAS Boston Scientific is the owner of the Jang Patents (as later defined herein);

B. WHEREAS J&J/Cordis is the owner of the Palmaz and Gray Patents (as later defined herein);

C. WHEREAS Boston Scientific, J&J/Cordis and certain of their Affiliates are parties to
Pending Litigations (as defined hereunder) in the United States in which the Jang Patents are
being asserted by Boston Scientific and the Palmaz and Gray Patents are being asserted by Cordis;

D. WHEREAS the Parties have agreed to settle the specified Pending Litigations on the terms
set forth herein; and

E. WHEREAS the Parties have agreed to grant each other retroactive, paid up, irrevocable,
non-exclusive cross-licenses under the Jang Patents, and the Palmaz and Gray Patents, on the terms
and subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the promises and the mutual covenants set forth herein,
the sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

	1.	 	DEFINITIONS

In addition to the terms defined above and elsewhere in this Agreement, as used in this
Agreement:

	 	1.1.	 	"Affiliate” or “Affiliates” shall mean any corporation, company, or other
business entity that directly, or indirectly through one or more intermediaries, is
controlled by or under common control with either Boston Scientific Corporation, Boston
Scientific Scimed, Inc., Boston Scientific Vascular Successor, Johnson & Johnson,
Cordis Corporation, or Cordis Successor, respectively, but only for so long as such
control relationship exists. For such purpose, “control” shall mean (1) the
possession, directly or indirectly through one or more intermediaries, of the power to
direct or cause the direction of the management and/or policies of the entity, whether
through the ownership of voting securities, by contract or otherwise or (2) ownership,
directly or indirectly, of more than fifty percent (50%) (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a particular
jurisdiction) of the equity or other ownership interest having the power to vote on or
direct the affairs of such corporation, firm, partnership, joint venture or other
entity.

	 	1.2.	 	“Boston Scientific’s Vascular Business” shall mean the business units of Boston
Scientific that are substantially involved in the manufacture, development and sale of
products used in vascular intervention and endovascular procedures, including, balloon
catheters, atherectomy devices, guidewires, guiding catheters, stents, drug-eluting
stents, bioabsorbable and/or biodegradable stents, stent coatings, and embolic
protection devices. Notwithstanding the foregoing, Boston Scientific’s Vascular
Business shall not include the business units of Boston Scientific that are primarily
involved in the manufacture, development and sale of products that are primarily used
in cardiac rhythm management.

	 	1.3.	 	“Jang Patents” shall mean U.S. patents: 5,922,021; 5,954,743; 6,039,756;
6,152,957; 6,235,053; 6,241,760; 6,409,761; 6,770,088; 6,783,543; 7,081,130; 7,326,241;
owned by Boston Scientific or its Affiliates, any U.S. and non-U.S. counterparts of the
foregoing patents, any reissues or reexamination certificates that have issued or issue
from any of the foregoing patents, and any patents that have issued or issue from any
application that claims the benefit of a U.S. or non-U.S. filing date that is claimed
by the foregoing patents and patent applications, including any provisional,
continuation, continuation in part, division or substitution thereof.

	 	1.4.	 	“Licensed Product(s)” shall mean any product or service (i) made by or for
Boston Scientific (including Affiliates) or Cordis Corporation (including Affiliates)
and (ii) externally marketed and offered for sale by or for such Party (including
Affiliates) and under such Party’s (including Affiliate’s) branding in the Territory,
including, but not limited to, the products that were accused of infringement in one or
more of the Pending Litigations, and further including Boston Scientific’s Taxus,
Liberte, Taxus Liberte, Express and Taxus Express Stent products, and Cordis’s Cypher
Stent products with the sole exception of Cordis’s 2.25 mm Cypher Mini Stent that is
the subject of the infringement allegation in Cordis Corporation v Boston Scientific
Corporation et al, CA No. 0:09-cv-03445(D. Minn.) (also referred to as the “Minnesota
District Court Action”).

	 	1.5.	 	“Palmaz and Gray Patents” shall mean U.S. Patent Nos. 4,733,665; 4,739,762;
4,776,337; 5,102,417; 5,195,984; and 5,902,332 (Palmaz); and 5,895,406; 5,938,682;
5,980,553; and 6,162,243 (Gray) which are owned by J&J/Cordis or its Affiliates, any
U.S. and non-U.S. counterparts of the foregoing patents, any reissues or
reexamination certificates that have issued or issue from any of the foregoing
patents, and any patents that have issued or issue from any application that claims
the benefit of a U.S. or non-U.S. filing date that is claimed by the foregoing patents
and patent applications, including any provisional, continuation, continuation in part,
division or substitution thereof.

	 	1.6.	 	“Pending Litigations” shall mean, collectively:

(a) The Cordis Corporation v. Boston Scientific Corporation and Scimed Life Systems,
Inc., CA No. 1:03-cv-00027 (D. Del.) litigation, hereinafter referred to as the
“Cypher/Express/Taxus Express/Liberte District Court Action” , and

(b) The Cordis Corporation v Boston Scientific Corporation and Boston Scientific
Scimed, Inc., CA 1:08-cv-779 (D. Del.) litigation, hereinafter referred to as the
“Taxus Liberte District Court Action.”

	 	1.7.	 	“Stent” shall mean a medical device to be placed into a lumen in a body to
maintain patency by supporting the lumen against closure or re-closure, or to
mechanically support or expand the lumen thereby serving as a scaffold or matrix to
present a material to the wall of such lumen.

	 	1.8.	 	“Territory” shall mean worldwide.

	2.	 	PAYMENT

	 	2.1.	 	Boston Scientific shall pay or cause to be paid to Johnson & Johnson the
aggregate amount of one billion seven hundred twenty-five million dollars
($1,725,000,000.00) plus interest, in the manner and in such amounts as set forth in
this Section 2. Any payment provided in this Section 2 shall be made by wire transfer
to the following account:

Bank Name                 JP Morgan Chase Bank

ABA Number            

Swift ID:

Account Name            Johnson & Johnson

Account Number       

	 	2.2.	 	By 3:00 PM EST on February 1, 2010, Boston Scientific shall pay or cause to be
paid to Johnson & Johnson the amount of one billion ($1,000,000,000.00) by wire
transfer to the bank and account identified in Section 2.1.

	 	2.3.	 	By 12:00 PM EST on January 3, 2011, Boston Scientific shall pay or cause to be
paid to Johnson & Johnson the amount of seven hundred twenty-five million dollars
($725,000,000.00) by wire transfer to the bank and account identified in Section 2.1.

	 	2.4.	 	Boston Scientific shall pay or cause to be paid interest on the seven hundred
twenty-five million dollars ($725,000,000.00) due pursuant to Section 2.3 at the prime
rate of interest (as published on the first business day of each month in the Wall
Street Journal), rate adjusted monthly, applied to the prior month period and payable
on the third business day of each month with respect to the period following the
Effective Date through the last date of payment hereunder, by wire transfer to the bank
and account identified in Section 2.1.

	 	2.5.	 	By 3:00 PM EST on February 1, 2010, Boston Scientific shall cause an
irrevocable letter of credit in the amount of seven hundred forty-five million
($745,000,000) to be issued by Bank of America, in the form attached as Exhibit A, and
otherwise suitable to J&J/Cordis, guaranteeing payment of the seven hundred twenty-five
million dollars ($725,000,000.00) and interest due pursuant to Sections 2.3 and 2.4.

	 	2.6.	 	(a) In the event that Boston Scientific fails to make all or part of the
$725,000,000 payment when due on January 3, 2011 in accordance with Section 2.3, then
J&J/Cordis shall immediately be entitled to draw down on the irrevocable letter of
credit in the unpaid amount then due.

(b) In the event that Boston Scientific fails to timely make any interest payment
when due in accordance with Section 2.4, then J&J/Cordis shall immediately be
entitled to draw down on the irrevocable letter of credit in the unpaid amount then
due, not to exceed for all unpaid interest payments the aggregate of $20,000,000.

(c) In the event that Boston Scientific owes any amount in excess of the amount
available under the irrevocable letter of credit, Boston Scientific shall promptly
make separate payment of such amount to J&J/Cordis by wire transfer to the account
identified in Section 2.1.

	3.	 	SETTLEMENT, JUDGMENT AND SATISFACTION

	 	3.1.	 	Boston Scientific and Cordis hereby settle the Pending Litigations and shall
consent to the entry of judgment as to all remaining claims in the Pending
Litigations, including the Cypher/Express/Taxus Express/Liberte District Court Action
and the Taxus Liberte District Court Action, and to a final judgment of damages to be
paid by Boston Scientific to Cordis in the amount of one billion seven hundred
twenty-five million dollars ($1,725,000,000.00), by executing and filing the “Consent
Judgment” in the form attached as Exhibit B which shall be executed and filed with the
court no later than February 1, 2010.

	 	3.2.	 	As long as all payments are timely made by or for Boston Scientific pursuant to
Sections 2.2., 2.3, and 2.4, and the irrevocable letter of credit is timely issued by
Bank of America pursuant to Section 2.5, Cordis agrees to refrain from executing on
this judgment.

	 	3.3.	 	In the event that all payments due to J&J/Cordis hereunder are paid in full in
accordance with this Agreement, and Boston Scientific shall have performed each of its
obligations hereunder in all material respects as of January 3, 2011, Cordis shall then
agree that such judgment referred to in Section 3.1 has been satisfied.

	 	3.4.	 	Each Party shall each bear its own costs, expenses, and attorney fees in
connection with this Agreement and the Pending Litigations, regardless of any costs,
expenses, and attorney fees that have already been awarded by a judicial tribunal,
except that Cordis shall be entitled to collect its attorneys fees and costs in
connection with any collection of any overdue amounts not timely paid pursuant to
Section 2. No party shall otherwise seek any costs in any of the Pending Litigations.

	 	3.5.	 	The existence and/or terms of this Agreement shall not be used in any
litigation between the Parties, including any Affiliates of the Parties, except in an
action (1) to enforce the terms of the Agreement, (2) to obtain and, if necessary
enforce, the final judgment as set forth in Section 3 or (3) for damages associated
with the breach of the Agreement.

	4.	 	J&J/CORDIS’S LICENSE TO THE JANG PATENTS

	 	4.1.	 	Grant of License from Boston Scientific to J&J/Cordis.

(a) Subject to the terms and conditions of this Agreement, Boston Scientific hereby
grants J&J/Cordis and its Affiliates a retroactive, non-exclusive, personal,
non-transferable (except as expressly set forth herein), paid-up, perpetual, and
irrevocable license under the Jang Patents to make, have made, use, sell, offer for
sale, export and import the Licensed Products in the Territory.

(b) J&J/Cordis may assign, delegate, sell or transfer (each collectively,
“transfer”) all rights and responsibilities hereunder this Agreement to a purchaser
acquiring the capital stock of or all or substantially all of the assets of Cordis
Corporation (hereinafter “Cordis Successor”), without obtaining the prior written
consent of Boston Scientific, provided that: (1) any such Cordis Successor
immediately consents in writing to be bound by the terms and conditions of this
Agreement; (2) no such potential Cordis Successor, or any of its Affiliates, has
operated a Stent or Stent-related businesses prior to such transfer; and (3) the
license rights transferred to any such Cordis Successor shall extend only to the
Licensed Products that are commercially released or for which significant steps have
been taken to commercialization as of the effective date of the divestiture (“Cordis
Covered Products”) and for new versions of such Cordis Covered Products that have
merely incremental differences from such Cordis Covered Products and shall not in
any event include any products, processes, technologies or services of the Cordis
Successor, any Affiliate of the Cordis Successor, or any other third party. This
Section 4.1(b) shall apply regardless of whether the business is divested by a
distribution to existing shareholders, a sale of assets or as a sale of a legal
entity (e.g., sale of a subsidiary). Johnson & Johnson, or the Cordis Successor if
Johnson & Johnson shall no longer have a separate corporate existence, shall, within
thirty (30) days after any such transfer provide Boston Scientific with written
notice, which notice will contain: (i) the effective date of the divestiture; (ii)
a description of the transaction through which the divestiture occurred; and
(iii) reasonably detailed information regarding the Covered Products. The Cordis
Successor may not further transfer the transferred license rights, or any portion
thereof (by operation of law or otherwise). The transferred license rights will
immediately terminate upon any such attempted further transfer (by operation of law
or otherwise), and any such attempted further transfer will be null and void.

(c) This Agreement shall have no effect on Boston Scientific’s right to assert any
patent not identified as a Jang Patent in this Agreement.

	 	4.2.	 	No Other Rights. Nothing contained in this Agreement shall be construed as
conferring any rights by implication, estoppel or otherwise, under any intellectual
property, other than the rights expressly granted in this Agreement with respect to the
Jang Patents. In particular, J&J/Cordis shall have no right to sublicense, assign or
otherwise grant any rights under the Jang Patents except as expressly provided in
Section 4.1(b). All rights not expressly granted above or otherwise in this Agreement
are expressly reserved by Boston Scientific.

	 	4.3.	 	Company Liable for Obligations of Affiliates. J&J/Cordis shall cause all of
its Affiliates to comply with and perform all obligations and covenants under each and
every term and condition of this Agreement. J&J/Cordis Corporation is and shall remain
primarily liable to Boston Scientific for all of its Affiliates’ obligations,
covenants, representations and performance under each and every term and condition of
this Agreement.

	5.	 	BOSTON SCIENTIFIC’S LICENSE TO THE PALMAZ AND GRAY PATENTS

	 	5.1.	 	Grant of License from J&J/Cordis to Boston Scientific.

(a) Subject to the terms and conditions of this Agreement, J&J/Cordis hereby grants
Boston Scientific and its Affiliates a retroactive, non-exclusive, personal,
non-transferable (except as expressly set forth herein), paid-up, perpetual, and
irrevocable license under the Palmaz and Gray Patents to make, have made, use, sell,
offer for sale, export and import the Licensed Products in the Territory.

(b) Boston Scientific may assign, delegate, sell or transfer (each collectively,
“transfer”) all rights and responsibilities hereunder this Agreement to a purchaser
acquiring all or substantially all of the assets of Boston Scientific’s Vascular
Business (hereinafter “Boston Scientific Vascular Successor”), without obtaining the
prior written consent of J&J/Cordis, provided that: (1) any such Boston Scientific
Vascular Successor immediately consents in writing to be bound by the terms and
conditions of this Agreement; (2) no such potential Boston Scientific Vascular
Successor, or any of its Affiliates, has operated a Stent or Stent-related
businesses prior to such transfer; and (3) the license rights transferred to any
such Boston Scientific Vascular Successor shall extend only to the Licensed Products
of Boston Scientific that are commercially released or for which significant steps
have been taken to commercialization as of the effective date of the divestiture
(“Boston Scientific Covered Products”) and for new versions of such Boston
Scientific Covered Products that have merely incremental differences from such
Boston Scientific Covered Products and shall not in any event include any products,
processes, technologies or services of the Boston Scientific Vascular Successor, any
Affiliate of the Boston Scientific Vascular Successor, or any other third party.
This Section 5.1(b) shall apply regardless of whether the business is divested by a
distribution to existing shareholders, a sale of assets or as a sale of a legal
entity (e.g., sale of a subsidiary). Boston Scientific, or the Boston Scientific
Vascular Successor if Boston Scientific shall no longer have a separate corporate
existence, shall, within thirty (30) days after any such transfer provide J&J/Cordis
with written notice, which notice will contain: (1) the effective date of the
divestiture; (2) a description of the transaction through which the divestiture
occurred; and (3) reasonably detailed information regarding the Boston Scientific
Covered Products. The Boston Scientific Vascular Successor may not further transfer
the transferred license rights, or any portion thereof (by operation of law or
otherwise). The transferred license rights will immediately terminate upon any such
attempted further transfer (by operation of law or otherwise), and any such
attempted further transfer will be null and void.

(c) This Agreement shall have no effect on J&J/Cordis’ right to assert any patent
not identified as a Palmaz or Gray Patent in this Agreement.

	 	5.2.	 	No Other Rights. Nothing contained in this Agreement shall be construed as
conferring any rights by implication, estoppel or otherwise, under any intellectual
property, other than the rights expressly granted in this Agreement with respect to the
Palmaz and Gray Patents. In particular, Boston Scientific shall have no right to
sublicense, assign or otherwise grant any rights under the Palmaz and Gray Patents
except as expressly provided in Sections 5.1(b). All rights not expressly granted
above or otherwise in this Agreement are expressly reserved by J&J/Cordis.

	 	5.3.	 	Company Liable for Obligations of Affiliates. Boston Scientific shall cause
all of its Affiliates to comply with and perform all obligations and covenants under
each and every term and condition of this Agreement. Boston Scientific is and shall
remain primarily liable to J&J/Cordis for all of its Affiliates’ obligations,
covenants, representations and performance under each and every term and condition of
this Agreement.

	6.	 	RELEASES

	 	6.1.	 	Release by Boston Scientific. In addition to the entry of consent judgment in
the Pending Litigations, Boston Scientific, on its own behalf and on behalf of its
Affiliates, hereby releases and discharges J&J/Cordis and its Affiliates and its and
their successors, assigns, directors, officers, employees, agents and customers from
all causes of action, demands, claims, damages and liabilities of any nature, whether
known or unknown, arising from or in connection with the Jang Patents only, occurring
prior to the Effective Date of this Agreement, including, without limitation, all
claims that Boston Scientific or any of its Affiliates have asserted or could have
asserted in any judicial proceeding that the Jang Patents have been infringed by
J&J/Cordis or its Affiliates in the Territory. The sole exception to this release is
Boston Scientific’s infringement claim directed to Cordis’s 2.25 mm Cypher Mini Stent
that is the subject of Cordis Corporation v Boston Scientific Corporation et al, CA No.
0:09-cv-03445(D. Minn.).

	 	6.2.	 	Release by J&J/Cordis. In addition to the entry of consent judgment in the
Pending Litigations, J&J/Cordis, on its own behalf and on behalf of its Affiliates,
hereby releases and discharges Boston Scientific and its Affiliates and its and their
successors, assigns, directors, officers, employees, agents and customers from all
causes of action, demands, claims, damages and liabilities of any nature, whether known
or unknown, arising from or in connection with the Palmaz and Gray Patents only,
occurring prior to the Effective Date of this Agreement, including, without limitation,
all claims that J&J/Cordis or any of its Affiliates have asserted or could have
asserted in any judicial proceeding that the Palmaz and Gray Patents have been
infringed by Boston Scientific or its Affiliates in the Territory.

	 	6.3.	 	Limits On Releases. The releases granted in this Agreement shall not be used
in any litigation as evidence that a product or service or hypothetical product or
service is a non-infringing alternative.

	7.	 	REPRESENTATIONS, WARRANTIES, AND INDEMNIFICATIONS

	 	7.1.	 	Representations and Warranties of Boston Scientific. Boston Scientific
represents and warrants that: (i) it has full corporate power and authority to execute
and deliver this Agreement and the irrevocable letter of credit, to consummate the
transactions contemplated hereby and to bind its Affiliates as set forth herein; (ii)
it or its Affiliates own the entire right, title and interest in the Jang Patents; and
(iii) neither it nor any of its Affiliates have granted and will not grant any licenses
or other rights, under the Jang Patents or otherwise, that would conflict with or
prevent the enjoyment of the rights granted to J&J/Cordis and its Affiliates hereunder.

	 	7.2.	 	Representations and Warranties of J&J/Cordis. J&J/Cordis represents and
warrants that: (i) it has full corporate power and authority to execute and deliver
this Agreement, to consummate the transactions contemplated hereby and to bind its
Affiliates as set forth herein; (ii) it or its Affiliates own the entire right, title
and interest in the Palmaz and Gray Patents; and (iii) neither it nor any of its
Affiliates have granted and will not grant any licenses or other rights, under the
Palmaz and Gray Patents or otherwise, that would conflict with or prevent the enjoyment
of the rights granted to Boston Scientific hereunder.

	 	7.3.	 	Indemnification by Boston Scientific: Boston Scientific shall indemnify, defend
and hold harmless J&J/Cordis, and each of its and their respective employees, officers,
directors and agents (for purposes of this Section 7.3, collectively “the Indemnified
Party”) from and against any and all liability, loss, damage, cost, and expense
(including reasonable attorneys’ fees) that the Indemnified Party may incur, suffer or
be required to pay due to a breach of any covenant, representation or warranty
contained in this Agreement, including, but not limited to, any claims by G. David
Jang, his successors, agents, licensees, or assigns, with respect to the Jang Patents.
In the event that G. David Jang brings an action against J&J/Cordis with respect to the
Jang Patents, Boston Scientific will have the right to control the action and Cordis
will reasonably cooperate with Boston Scientific.

	 	7.4.	 	Indemnification by J&J/Cordis: J&J/Cordis shall indemnify, defend and hold
harmless Boston Scientific, and each of its and their respective employees, officers,
directors and agents (for purposes of this Section 7.4, collectively “the Indemnified
Party”) from and against any and all liability, loss, damage, cost, and expense
(including reasonable attorneys’ fees) that the Indemnified Party may incur, suffer or
be required to pay due to a breach of any covenant, representation or warranty
contained in this Agreement.

	 	7.5.	 	No Other Representations, Warranties, and Indemnifications. OTHER THAN AS
EXPRESSLY SET FORTH IN SECTIONS 7.1 AND 7.2 ABOVE, NEITHER BOSTON SCIENTIFIC NOR
J&J/CORDIS MAKE ANY REPRESENTATIONS OR EXTEND WARRANTIES OR INDEMNIFICATIONS OF ANY
KIND EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF ANY PRODUCTS
WILL NOT INFRINGE ANY COPYRIGHT, PATENT, TRADEMARK, OR OTHER RIGHTS.

	8.	 	CONFIDENTIALITY

The terms of this Agreement shall be maintained in strict confidence by the Parties except
that either Party may disclose such terms as required by law, including without limitation
SEC reporting requirements. Either Party may further disclose the fact of the settlement of
the Pending Litigations, the consent judgment entered, and the specifics relating to the
amounts, nature and timing of the payments made and to be made.

	9.	 	TERM AND TERMINATION

	 	9.1.	 	Term. This Agreement shall commence as of the Effective Date, after the
Parties’ signatures of this Agreement, and shall terminate after the expiration of the
last to expire of the Licensed Patents (“Term”).

	 	9.2.	 	Termination. This Agreement may only be terminated by mutual written agreement
of the Parties.

	10.	 	NEGATION OF AGENCY

Nothing herein contained shall be deemed to create any relationship in the nature of agency,
joint venture, partnership, or similar relationship between Boston Scientific, J&J/Cordis
and their Affiliates. Neither Party shall be authorized to bind or obligate the other Party
in any manner.

	11.	 	NOTICE

Any notice required or permitted to be given or sent under this Agreement shall be hand
delivered or sent by express delivery service or certified or registered mail, postage
prepaid, to the Parties at the addresses indicated below.

	 	 	 
	If to Boston Scientific, to:

with copies to:
	 	Attn: General Counsel

Boston Scientific Corporation

1 Boston Scientific Place

Natick, Massachusetts 01760

John M. Desmarais

Kirkland & Ellis

601 Lexington Avenue

New York, NY 10022

	If to J&J/Cordis, to:

with copies to:
	 	Attn: General Counsel

Johnson & Johnson

One Johnson & Johnson Plaza

New Brunswick, New Jersey 08933

Gregory L. Diskant

Patterson Belknap Webb & Tyler LLC

Avenue of the Americas

New York, New York 10036

Any such notice shall be deemed to have been received on the date actually received. Either
Party may change its address by giving the other Party written notice, delivered in
accordance with this Section.

	12.	 	ENTIRE AGREEMENT

This Agreement and its exhibits constitute the complete, final and exclusive agreement
between the Parties with respect to the subject matter hereof and supersede and terminate
any prior or contemporaneous agreements and understandings between the Parties, whether oral
or in writing, relating to such subject matter. There are no covenants, promises,
agreements, warranties, representations, conditions or understandings, either oral or
written, between the Parties other than as are set forth herein. No subsequent alteration,
amendment, change, waiver or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party. Each Party in
deciding to execute this Agreement has retained counsel and has not relied on any
understanding, agreement, representation or promise by the other Party that is not
explicitly set forth herein.

	13.	 	GOVERNING LAW

This Agreement and its exhibits shall be governed, interpreted and construed in accordance
with the laws of the State of Delaware, without giving effect to choice of law principles.
The Parties irrevocably agree that the federal district court in the State of Delaware shall
have exclusive jurisdiction to deal with any disputes arising out of or in connection with
this Agreement and that, accordingly, any proceedings arising out of or in connection with
this Agreement shall be brought in the United States District Court for the District of
Delaware. Notwithstanding the foregoing, if there is any dispute for which the federal
district courts in the State of Delaware do not have subject matter jurisdiction, the state
courts in Delaware shall have jurisdiction. In connection with any dispute arising out of
or in connection with this Agreement, each Party hereby expressly consents and submits to
the personal jurisdiction of the federal and state courts in the State of Delaware.

	14.	 	SEVERABILITY

If one or more provisions of this Agreement is held to be invalid or unenforceable under
applicable law, such provision shall be excluded from this Agreement and the balance of the
Agreement shall be interpreted as if such provision were so excluded. In the event a part
or provision of this Agreement is held to be invalid or unenforceable or in conflict with
law for any reason, the Parties shall replace any invalid part or provision with a valid
provision which most closely approximates the intent and economic effect of the invalid
provision.

	15.	 	COUNTERPARTS

This Agreement shall become binding when any one or more counterparts hereof, individually
or taken together, bears the signatures of each of the Parties hereto. This Agreement may
be executed in any number of counterparts (including facsimile counterparts), each of which
shall be an original as against a Party whose signature appears thereon, but all of which
taken together shall constitute one and the same instrument.

	16.	 	THIRD PARTY BENEFICIARIES AND ASSIGNMENTS

	 	16.1.	 	Nothing in this Agreement shall be construed to give rise to any right or
obligation for the benefit of a third party or to confer any rights on any party other
than Boston Scientific or J&J/Cordis and their Affiliates. Except as otherwise
specified in Sections 4.1(b) and 5.1(b), neither Party may assign, delegate, sell,
transfer, sublicense or otherwise dispose of, voluntarily or involuntarily, by
operation of law or otherwise, any or all of its rights or obligations under this
Agreement to any other person, business or entity other than its Affiliates without the
other Party’s written consent, and any purported assignment or transfer in violation of
this Section 16 shall be null and void.

	 	16.2.	 	For the avoidance of doubt, any assignment or other transfer of any license
rights hereunder is prohibited unless the assignee or transferee has first agreed in
writing to be bound by the terms and conditions of this Agreement, and any purported
assignment or transfer in violation of this requirement shall be null and void.

	 	16.3.	 	For the avoidance of doubt, any assignment or other transfer of any rights
(not including a non-exclusive license) to any of the Jang Patents or Palmaz and Gray
Patents is prohibited unless the assignee or transferee has first agreed in writing to
be bound by the terms and conditions of this Agreement, and any purported assignment or
transfer in violation of this requirement shall be null and void.

	17.	 	CONSULTATION WITH COUNSEL AND RELIANCE

Each of the Parties acknowledges that it has consulted with, or has had the opportunity to
consult with, counsel of its choice, and that in executing this Agreement it has not relied
upon any statements, representations or agreements of any other person other than those
contained herein.

	18.	 	CAPTIONS

Captions are inserted herein only as a matter of convenience and for reference, and in no
way define, limit, or describe the scope of this Agreement or the intent of any provision
herein.

	19.	 	CONSTRUCTION

This Agreement has been jointly negotiated and drafted by the Parties through their
respective counsel and no provision shall be construed or interpreted for or against any of
the Parties on the basis that such provision, or any other provision, or the Agreement as a
whole, was purportedly drafted by the particular Party. All references to periods of days
for taking certain actions in this Agreement shall be construed to refer to business days.

1

* * * * *

IN WITNESS WHEREOF, the parties’ authorized representatives have executed this Agreement on the
dates set forth below.

	 	 	 
	Boston Scientific Corporation	 	Johnson & Johnson
	By:       

	 	By:     
	Print Name:       

	 	Print Name:      
	Title:       

	 	Title:      
	Date:      

	 	Date:      
	Boston Scientific Scimed, Inc.

	 	Cordis Corporation
	By:       

	 	By:     
	Print Name:       

	 	Print Name:      
	Title:       

	 	Title:      
	Date:      

	 	Date:      

2

EXHIBIT A

[LETTERHEAD OF ISSUER OF LETTER OF CREDIT]

FEBRUARY 1 , 2010

	 	 	 
	BENEFICIARY: JOHNSON & JOHNSON APPLICANT:
	BENEFICIARY ADDRESS BOSTON SCIENTIFIC CORPORATION
	ATTENTION: ONE BOSTON SCIENTIFIC PLACE
	 	 	NATICK, MA 01760

	REF:
	 	IRREVOCABLE LETTER OF CREDIT NO.   

GENTLEMEN:

WE HEREBY OPEN OUR UNCONDITIONAL IRREVOCABLE CLEAN LETTER OF CREDIT NO.        IN YOUR FAVOR
AVAILABLE BY YOUR DRAFT(S) AT SIGHT FOR AN AMOUNT NOT TO EXCEED IN THE AGGREGATE OF SEVEN HUNDRED
FORTY-FIVE MILLION DOLLARS ($745,000,000.00). WE ARE INFORMED BY THE APPLICANT THAT THIS LETTER OF
CREDIT IS ISSUED IN REGARDS TO THIS CERTAIN ”SETTLEMENT AGREEMENTAND NON-EXCLUSIVE PATENT
CROSS-LICENSE” BY AND BETWEEN, ON THE ONE HAND, BOSTON SCIENTIFIC CORPORATION AND, ON THE OTHER
HAND, JOHNSON & JOHNSON AND CORDIS CORPORATION, DATED JANUARY 29, 2010, (hereinafter the
“Settlement Agreement”) EFFECTIVE IMMEDIATELY.

ALL DRAFTS SO DRAWN MUST BE MARKED “DRAWN UNDER IRREVOCABLE LETTER OF CREDIT OF [ISSUING BANK],
NO.       , DATED FEBRUARY 1, 2010” MULTIPLE DRAWINGS MAY BE MADE UNDER THIS LETTER OF CREDIT
AND EACH DRAWING HONORED BY US WILL REDUCE THE AMOUNT AVAILABLE FOR DRAWING UNDER THIS LETTER OF
CREDIT BY THE AMOUNT OF SUCH DRAWING.

THIS LETTER OF CREDIT IS ISSUED, PRESENTABLE AND PAYABLE AT OUR OFFICE AT
     , OR SUCH OTHER OFFICE AS WE MAY DESIGNATE BY WRITTEN NOTICE TO YOU, AND
EXPIRES WITH OUR CLOSE OF BUSINESS ON JANUARY 31, 2011. ANY DRAFTS TO BE DRAWN MAY BE PRESENTED BY
FACSIMILE TO OUR FAX NUMBER 1.800.755.8743. IF PRESENTATION IS BY FACSIMILE, THE ORIGINAL DRAFT
MUST BE SENT BY OVERNIGHT COURIER THE SAME DAY AS THE FAX PRESENTATION. ANY FAX PRESENTATIONS MUST
ALSO BE IMMEDIATELY FOLLOWED UP WITH A PHONE CALL TO 1.570.330.4213 TO CONFIRM RECEIPT.

ALL DRAWINGS MUST BE MADE BY PRESENTATION OF A SIGHT DRAFT IN THE FORM OF SCHEDULE A ATTACHED
HERETO ACCOMPANIED BY THE FOLLOWING:

—WITH RESPECT TO AMOUNTS DUE UNDER SECTION 2.3 OF THE SETTLEMENT AGREEMENT, A BENEFICIARY’S
STATEMENT SIGNED BY THE GENERAL COUNSEL OF THE BENEFICIARY READING SUBSTANTIALLY AS FOLLOWS:

“BOSTON SCIENTIFIC CORPORATION HAS FAILED TO PAY TO JOHNSON & JOHNSON ALL OR PART OF THE
$725,000,000 PAYMENT AS AND WHEN DUE ON JANUARY 3, 2011 UNDER SECTION 2.3 OF THE SETTLEMENT
AGREEMENT AND JOHNSON & JOHNSON IS THEREFORE ENTITLED TO PAYMENTS IN THE AMOUNT OF $     .
PAYMENT WILL BE EFFECTED IMMEDIATELY UPON RECEIPT OF THE ORIGINAL SIGHT DRAFT AND THE EXECUTED
BENEFICIARY’S STATEMENT AT OUR ABOVE OFFICE.”

—WITH RESPECT TO AMOUNTS DUE UNDER SECTION 2.4 OF THE SETTLEMENT AGREEMENT, A BENEFICIARY’S
STATEMENT SIGNED BY THE GENERAL COUNSEL OF THE BENEFICIARY READING SUBSTANTIALLY AS FOLLOWS:

“BOSTON SCIENTIFIC CORPORATION HAS FAILED TO PAY TO JOHNSON & JOHNSON ALL OR PART OF INTEREST
PAYMENTS AS AND WHEN DUE UNDER SECTION 2.4 OF THE SETTLEMENT AGREEMENT, NOT TO EXCEED $20,000,000
IN THE AGGREGATE FOR UNPAID INTEREST, AND JOHNSON & JOHNSON IS THEREFORE ENTITLED TO PAYMENTS IN
THE AMOUNT OF $     . PAYMENT WILL BE EFFECTED IMMEDIATELY UPON RECEIPT OF THE ORIGINAL SIGHT
DRAFT AND THE EXECUTED BENEFICIARY’S STATEMENT AT OUR ABOVE OFFICE.”

THIS LETTER OF CREDIT IS TRANSFERABLE IN FULL AND NOT IN PART. ANY TRANSFER MADE HEREUNDER MUST
CONFORM STRICTLY TO THE TERMS HEREOF AND TO THE CONDITIONS OF ARTICLE 38 OF THE UNIFORM CUSTOMS AND
PRACTICE FOR DOCUMENTARY CREDITS (2007 REVISION) FIXED BY THE INTERNATIONAL CHAMBER OF COMMERCE,
PUBLICATION NO. 600.

SHOULD YOU WISH TO EFFECT A TRANSFER UNDER THIS CREDIT, SUCH TRANSFER WILL BE SUBJECT TO THE RETURN
TO US OF THE ORIGINAL CREDIT INSTRUMENT, ACCOMPANIED BY OUR FORM OF TRANSFER AVAILABLE UPON
REQUEST, PROPERLY COMPLETED AND SIGNED BY AN AUTHORIZED SIGNATORY OF YOUR FIRM, BEARING YOUR
BANKERS STAMP AND SIGNATURE AUTHENTICATION, AND OUR CUSTOMARY PAYMENT OF OUR TRANSFER CHARGES OF $
500.00 SHALL BE FOR THE ACCOUNT OF THE APPLICANT.

WE HEREBY DO UNDERTAKE TO PROMPTLY HONOR YOUR SIGHT DRAFT OR DRAFTS DRAWN ON US, INDICATING OUR
LETTER OF CREDIT NO.        FOR THE AMOUNT AVAILABLE TO BE DRAWN ON THIS LETTER OF CREDIT UPON
PRESENTATION OF YOUR SIGHT DRAFT IN THE FORM OF SCHEDULE A ATTACHED HERETO DRAWN ON US AT OUR
OFFICES SPECIFIED ABOVE DURING OUR USUAL BUSINESS HOURS ON OR BEFORE THE EXPIRATION DATE HEREOF.

EXCEPT AS EXPRESSLY STATED HEREIN, THIS UNDERTAKING IS NOT SUBJECT TO ANY AGREEMENTS, REQUIREMENTS
OR QUALIFICATION. OUR OBLIGATION UNDER THIS LETTER OF CREDIT IS OUR INDIVIDUAL OBLIGATION AND IS
IN NO WAY CONTINGENT UPON REIMBURSEMENT WITH RESPECT THERETO OR UPON OUR ABILITY TO PERFECT ANY
LIEN, SECURITY INTEREST OR ANY OTHER REIMBURSEMENT.

THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS — 2007
REVISION, INTER-NATIONAL CHAMBER OF COMMERCE PUBLICATION NO. 600, AND AS TO MATTERS NOT GOVERNED BY
THE UCP, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK
AND APPLICABLE U.S. LAW.

[ISSUER OF LETTER OF CREDIT]

3

SCHEDULE A -FORM OF SIGHT DRAFT

(INSERT DATE OF SIGHT DRAFT, WHICH MUST BE DATE OF PRESENTMENT)

	 	 	 
	TO:
	 	BANK OF AMERICA, N.A.

1000 W. TEMPLE STREET, 7TH FL.

LOS ANGELES, CA 90012

ATTN: STANDBY LETTER OF CREDIT DEPARTMENT

FOR THE VALUE RECEIVED, PAY TO THE ORDER OF               BY WIRE
TRANSFER OF IMMEDIATELY AVAILABLE FUNDS TO THE FOLLOWING ACCOUNT:

[NAME OF ACCOUNT]

[ACCOUNT NUMBER]

NAME AND ADDRESS OF BANK AT WHICH ACCOUNT IS MAINTANED]

[ABA NUMBER]

[REFERENCE]

THE FOLLOWING AMOUNT:

[INSERT NUMBER OF DOLLARS IN WRITING] UNITED STATES DOLLARS (US$ [INSERT NUMBER OF DOLLARS IN
FIGURES])

DRAWN UPON YOUR IRREVOCABLE LETTER OF CREDIT NO.    DATED             , 2010.

{BENEFICIARY}

BY:       

TITLE:       

4

EXHIBIT B

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

      

	 	 	 	 	 
	CORDIS CORPORATION,

Plaintiff,

v.

BOSTON SCIENTIFIC CORPORATION

and BOSTON SCIENTIFIC SCIMED, INC.,

Defendants.

	 	)

)

)

)

)

)

)

)
	 	

C.A. No. 08-779-SLR

	 

	 	

	 	

      

	 	 	 	 	 
	CORDIS CORPORATION,

Plaintiff,

v.

BOSTON SCIENTIFIC CORPORATION

and SCIMED LIFE SYSTEMS, INC.,

Defendants.

	 	)

)

)

)

)

)

)

)
	 	

C.A. No. 03-027-SLR

	 

	 	

	 	

CONSENT JUDGMENT 

Whereas the parties in the two above-captioned actions have entered into a Settlement
Agreement and Non-Exclusive Patent Cross-License dated January 29, 2010 (hereinafter, “the
Agreement”) that settles all remaining claims between the parties in the above-captioned cases;

IT IS HEREBY ORDERED AND ADJUDGED that judgment be and is hereby entered in the amount of one
billion seven hundred twenty five million dollars ($1,725,000,000.00) payable by Boston Scientific
to Cordis pursuant to the terms of the Agreement.

Dated:      , 2010       

United States District Court JudgeS.CONT

     

Steven J. Balick (I.D. #2114)

John G. Day (I.D. #2403)

Ashby & Geddes

222 Delaware Avenue, 17th Floor

P.O. Box 1150

Wilmington DE 19899

(302) 654-1888

Attorneys for Plaintiff

Cordis Corporation

Of Counsel:

Gregory L. Diskant

Patterson Belknap Webb & Tyler llp

1133 Avenue of the Americas

New York, NY 10036

(212) 336-2000

Dated:      

     

Josy W. Ingersoll (No. 1088)

John W. Shaw (No. 3362)

Adam W. Poff (No. 3990)

YOUNG CONAWAY STARGATT

& TAYLOR, LLP

1000 West Street, 17th Floor

The Brandywine Building

Wilmington, Delaware 19801

(302) 571-6600

Attorneys for Defendants

Boston Scientific Corporation and

Boston Scientific Scimed, Inc.

Of Counsel:

John M. Desmarais

KIRKLAND & ELLIS LLP

Citigroup Center

601 Lexington Ave.

New York, New York 10022

(212) 446-4800

Dated:      

5exhibit_101.htm

    Exhibit
10.1

    FIRST
AMENDMENT

    TO

    AMENDED
AND RESTATED LOAN AND SECURITY AGREEMENT

     

     This
First Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is
entered into this 26th day
of January 2010, by and between Silicon Valley Bank (“Bank”) and Betawave
Corporation, a Delaware corporation (“Borrower”) whose
address is 706 Mission Street, 10th Floor, San Francisco, CA 94103.

     

    Recitals

     

    A.           Bank
and Borrower have entered into the Amended and Restated Loan and Security
Agreement, dated as of November 25, 2009 (as the same may from time to time be
amended, modified, supplemented or restated, the “Loan
Agreement”).

     

    B.           Bank
has extended credit to Borrower for the purposes permitted in the Loan
Agreement.

     

    C.           Borrower
has requested an extension of the maturity date.  Bank has agreed to
such request, but only to the extent, in accordance with the terms, subject to
the conditions and in reliance upon the representations and warranties set forth
below.

     

    Agreement

     

    Now,
Therefore, in consideration of the foregoing recitals and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, and intending to be legally bound, the parties hereto agree as
follows:

     

    1. Definitions.  Capitalized
terms used but not defined in this Amendment shall have the meanings given to
them in the Loan Agreement.

     

    2. Amendments
to Loan Agreement.

     

    2.1 Section
13.1                      (Definitions).  The
definition of “Maturity Date” in Section 13.1 of the Loan Agreement is amended
by deleting it in its entirety and replacing it with the following:

     

    “Maturity Date” is March 1,
2010.

     

    2.2 Section
13.1 (Definitions).  The definition of “Restructuring Fee Date” in
Section 13.1 of the Loan Agreement is amended by deleting it in its entirety and
replacing it with the following:

     

    “Restructuring Fee Date” is the
Maturity Date; provided, however, that if the Maturity Date is extended beyond
March 1, 2010 by Bank then the “Restructuring Fee Date” shall be the earlier to
occur of (a) the extended Maturity Date or (b) March 27, 2010.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    3. Limitation
of Amendments.

     

    3.1 The
amendments set forth in Section 2 above are effective for the purposes set forth
herein and shall be limited precisely as written and shall not be deemed to
(a) be a consent to any amendment, waiver or modification of any other term
or condition of any Transaction Document, or (b) otherwise prejudice any
right or remedy which Bank may now have or may have in the future under or in
connection with any Transaction Document.

     

    3.2 This
Amendment shall be construed in connection with and as part of the Transaction
Documents and all terms, conditions, representations, warranties, covenants and
agreements set forth in the Transaction Documents, except as herein amended, are
hereby ratified and confirmed and shall remain in full force and
effect.

     

    4. Representations and
Warranties.  To induce Bank to enter into this Amendment,
Borrower hereby represents and warrants to Bank as follows:

     

    4.1 Immediately
after giving effect to this Amendment (a) the representations and
warranties contained in the Transaction Documents are true, accurate and
complete in all material respects as of the date hereof (except to the extent
such representations and warranties relate to an earlier date, in which case
they are true and correct as of such date), and (b) no Event of Default has
occurred and is continuing;

     

    4.2 Borrower
has the power and authority to execute and deliver this Amendment and to perform
its obligations under the Loan Agreement, as amended by this
Amendment;

     

    4.3 The
organizational documents of Borrower most recently delivered to Bank remain
true, accurate and complete and have not been amended, supplemented or restated
and are and continue to be in full force and effect;

     

    4.4 The
execution and delivery by Borrower of this Amendment and the performance by
Borrower of its obligations under the Loan Agreement, as amended by this
Amendment, have been duly authorized;

     

    4.5 The
execution and delivery by Borrower of this Amendment and the performance by
Borrower of its obligations under the Loan Agreement, as amended by this
Amendment, do not and will not contravene (a) any law or regulation binding
on or affecting Borrower, (b) any contractual restriction with a Person
binding on Borrower, (c) any order, judgment or decree of any court or
other governmental or public body or authority, or subdivision thereof, binding
on Borrower, or (d) the organizational documents of Borrower;

     

    4.6 The
execution and delivery by Borrower of this Amendment and the performance by
Borrower of its obligations under the Loan Agreement, as amended by this
Amendment, do not require any order, consent, approval, license, authorization
or validation of, or filing, recording or registration with, or exemption by any
governmental or public body or authority, or subdivision thereof, binding on
either Borrower, except as already has been obtained or made; and

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    4.7 This
Amendment has been duly executed and delivered by Borrower and is the binding
obligation of Borrower, enforceable against Borrower in accordance with its
terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, liquidation, moratorium or other similar laws of general
application and equitable principles relating to or affecting creditors’
rights.

     

    5. Counterparts.  This
Amendment may be executed in any number of counterparts and all of such
counterparts taken together shall be deemed to constitute one and the same
instrument.

     

    6. Effectiveness.  This
Amendment shall be deemed effective upon (a) the due execution and delivery to
Bank of this Amendment by each party hereto, and (b) Borrower’s payment of
a facility fee in the amount of One Thousand Dollars ($1,000) in regard to the
extension of the Maturity Date set forth herein.

     

    [Signature
page follows.]

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    In Witness
Whereof, the parties
hereto have caused this Amendment to be duly executed and delivered as of the
date first written above.

     

    
      	
              BANK

            	
              BORROWER

            
	
               

              Silicon
      Valley Bank

               

               

              By: /s/
      Vincent Vallejos

              Name:  Vincent
      Vallejos                                                     

              Title:    Relationship
      Manager                       

            	
               

              Betawave
      Corporation

               

               

              By:  /s/
      David Lorie

              Name:   David
      Lorie                                

              Title:     Secretary
      and General
      Counsel                                                   

            

    

    

     

     

    4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]